Get the Stockscreener App
5.42
11.00%
-0.67
After Hours:
5.48
0.06
+1.11%
Pasithea Therapeutics Corp stock is traded at $5.42, with a volume of 228.47K.
It is down -11.00% in the last 24 hours and up +19.09% over the past month.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.
See More
Previous Close:
$6.09
Open:
$5.99
24h Volume:
228.47K
Relative Volume:
0.26
Market Cap:
$5.74M
Revenue:
-
Net Income/Loss:
$-16.28M
P/E Ratio:
-8.3385
EPS:
-0.65
Net Cash Flow:
$-13.75M
1W Performance:
+32.20%
1M Performance:
+19.09%
6M Performance:
-25.24%
1Y Performance:
-43.51%
1-Day Range:
$5.31
$6.07
1-Week Range:
$3.80
$7.50
52-Week Range:
$3.61
$17.40
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Name
Pasithea Therapeutics Corp
Sector
Industry
Phone
(818) 422-6172
Address
2110 NARCISSUS CT, VENICE
Pasithea Therapeutics Corp Stock (KTTA) Latest News
Was there any good news for Pasithea Therapeutics Corp (KTTA) stock in the last session? - US Post News
Allogene Therapeutics (ALLO) Stock Jumps by 5.15% - GuruFocus.com
Market cap of Pasithea Therapeutics Corp [KTTA] reaches 6.08M – now what? - The DBT News
PAS-004 Has Tolerable Safety Profile and Preliminary Efficacy in MAPK-Driven Solid Tumors - OncLive
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Stock Gains After Private Placement - DRP Journal
Grid Battery Metals Inc. (TSXV:CELL) (OTCQB:EVKRF) Stock Gains Momentum: Is It Sustainable? - DRP Journal
Pasithea Therapeutics prices $5M at-the-market private placement at $4.10/share - TipRanks
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - StockTitan
Technical Explosions: DUO, KTTA, TBIO, GOTUWatch Peraso Inc. (NASDAQ: PRSO) Now Amid Breakout Momentum! - openPR
Schwab Splitting Shares for Two-Thirds of ETF Lineup - Yahoo! Voices
Biotech Stock Pasithea Therapeutics Corp. (NASDAQ: KTTA) Soars on Positive Data from Phase 1 Clinical Trials - Investorideas.com newswire
Dow Surges Over 250 Points; Accenture Earnings Top Views - Benzinga
Stocks Stay Higher With Tech Still Driving Gains: Markets Wrap - Yahoo Finance
Why XPeng Stock Spiked Higher Today - Yahoo! Voices
Why Is Pasithea Therapeutics Stock Surging On Thursday? - AOL
KTTA’s price-to-free cash flow ratio: What it means for investors - US Post News
Crude Oil Down Over 2%; US Initial Jobless Claims Fall - Benzinga
English cricket ‘disconnected from reality’ in valuation of the Hundred - Yahoo! Voices
Pasithea Therapeutics Shares Move Higher After Positive Data for Cancer Treatment - MarketWatch
Visa agrees to buy AI-focused enterprise tech firm Featurespace - Yahoo! Voices
Pasithea Therapeutics (KTTA) Sees Strong Pre-Market Gains - Stocks Telegraph
Why Is Pasithea Therapeutics Stock Surging On Thursday? - Yahoo Finance
Pasithea Therapeutics rises on positive early-stage data from cancer drug - XM
Pasithea reports positive early data on cancer drug PAS-004 - Investing.com
Pasithea Therapeutics : Investor Presentation - Marketscreener.com
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), And Preliminary Efficacy Data From Its Phase 1 Clinical T... - MENAFN.COM
Pasithea Therapeutics announces initial data from Phase 1 trial of PAS-004 - TipRanks
Pasithea Therapeutics (KTTA) Reports Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from Phase 1 Trial of PAS-004 - StreetInsider.com
Pasithea Therapeutics Announces Positive Initial Safety, - GlobeNewswire
Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - StockTitan
Factbox-OpenAI key personnel changes - Yahoo! Voices
Why Viking Therapeutics Stock Was So Healthy on Wednesday - Yahoo Finance
Pasithea Therapeutics Corp. announced that it expects to receive $5.000003 million in funding - Marketscreener.com
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Capstan Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
BDTX-1535 Generates Early Signals of Antitumor Activity in R/R EGFR+ NSCLC - OncLive
The OncFive: Top Oncology Articles for the Week of 9/15 - OncLive
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate - Yahoo Finance
Are Robust Financials Driving The Recent Rally In TG Therapeutics, Inc.'s (NASDAQ:TGTX) Stock? - Yahoo Finance
Pasithea Therapeutics (NASDAQ:KTTA) Trading Up 25.8% - Defense World
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know - Yahoo Finance
KTTAPasithea Therapeutics Corp. Latest Stock News & Market Updates - StockTitan
Saghmos Therapeutics Announces Presentation at UBS 2024 Biotechnology Private Company Virtual Symposium - Yahoo Finance
Kalm Therapeutics Hires Former GSK Director Dr. Tomoko Maeda-Chubachi as Chief Medical Officer - Yahoo Finance
Why Investors Plowed Into Viking Therapeutics Stock Today - Yahoo Finance
Pasithea reports positive results in PAS-004 toxicity studies - Investing.com
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies - GlobeNewswire
Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies - StockTitan
Pasithea Therapeutics Corp Stock (KTTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):